PDGFRB Fusion

CI-VAR-00001472Explore in graph →CIViC 5196

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like2
ZEB2::PDGFRB Fusion	Dasatinib + ImatinibSubstitutes	Predictive	D	Supports Sensitivity Response	2	submitted	EID12481 Xenograft models of 10 Ph-like ALL tumors including ZEB2-PDGFRB were generated from engrafting primary human leukemia cells into NOD-SCID IL2R gamma null mice. The authors state that the xenograft cel… (full text at CIViC) Open in CIViC	civic
ZEB2::PDGFRB Fusion AND PAX5::BZW1 Fusion	(oncogenic)	Oncogenic	C	Supports Oncogenicity	2	submitted	EID12482 A patient is reported with karyotype 46,XX,del(12)(p13)[6]/46,XX[19] to have Ph-like other ALL of B-ALL Lineage by expression profiling. Age at diagnosis was 16.674, termed Adolescent and Young Adult,… (full text at CIViC) PMID 36050548 · Brady et al., 2022 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.